By using MEK1 inhibitor in combination with radiation therapy for advanced breast cancer, the miR-221 holds great potential as therapeutic marker of metastatic breast cancer and as promising target for new drug developments. This evidence concerns the gene MAP2K1 and breast carcinoma.